Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):389–392. doi: 10.1038/bjc.1993.346

Failure to detect early breast cancer using in vitro nuclear magnetic resonance spectroscopy of plasma.

L Holmberg 1, U Jakobsson 1, A Berglund 1, H O Adami 1
PMCID: PMC1968536  PMID: 8347495

Abstract

Water suppressed proton nuclear magnetic resonance (1H NMR) spectroscopy of human plasma has been described as successful in detection of malignancy. We designed a prospective study to test the hypothesis that in vitro NMR spectroscopy has a high sensitivity for detecting early breast cancer. One hundred and thirty-five women were referred for breast biopsy due to abnormal mammograms. One hundred of these were recruited through a population-based mammography screening project. Sixty-nine of 135 women were found to have breast cancer and their average line width of the methyl and methylene resonance in the plasma were compared to those women who had a benign or normal histopathology in the biopsy and to the line width for 100 healthy subjects from the same population. The mean line width at a half-height of the methyl and methylene resonances of the serum lipoprotein lipids in the NMR spectrum did not differ appreciably between the groups. The line width correlated highly with the serum triglycerides, but correction for the level of triglycerides did not improve the diagnostic accuracy of the line width. Receiver-operating characteristic analysis revealed a sensitivity of 61% and a false positive rate of 43% at the most beneficial cut-off of line width (39.7 Hz). In vitro NMR spectroscopy in our hands was thus not a useful diagnostic tool in patients with early breast cancer.

Full text

PDF
389

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell J. D., Sadler P. J., Macleod A. F., Turner P. R., La Ville A. 1H NMR studies of human blood plasma. Assignment of resonances for lipoproteins. FEBS Lett. 1987 Jul 13;219(1):239–243. doi: 10.1016/0014-5793(87)81224-3. [DOI] [PubMed] [Google Scholar]
  2. Berger S., Pflüger K. H., Etzel W. A., Fischer J. Detection of tumours with nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol. 1989 Mar;25(3):535–543. doi: 10.1016/0277-5379(89)90267-8. [DOI] [PubMed] [Google Scholar]
  3. Buchthal S. D., Hardy M. A., Brown T. R. Assessing the value of identifying the presence of malignant disease in human plasma by proton nuclear magnetic resonance spectroscopy. Am J Med. 1988 Oct;85(4):528–532. doi: 10.1016/s0002-9343(88)80090-1. [DOI] [PubMed] [Google Scholar]
  4. Engan T., Krane J., Klepp O., Kvinnsland S. Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer. N Engl J Med. 1990 Apr 5;322(14):949–953. doi: 10.1056/NEJM199004053221402. [DOI] [PubMed] [Google Scholar]
  5. Fossel E. T., Carr J. M., McDonagh J. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med. 1986 Nov 27;315(22):1369–1376. doi: 10.1056/NEJM198611273152201. [DOI] [PubMed] [Google Scholar]
  6. Herring F. G., Phillips P. S., Pritchard P. H. Proton magnetic resonance spectroscopy of plasma from patients with dyslipoproteinemia: identification of factors governing methyl and methylene proton line widths. J Lipid Res. 1989 Apr;30(4):521–528. [PubMed] [Google Scholar]
  7. Höfeler H., Scheulen M. E. Monitoring of patients with nonseminomatous testicular cancer by nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1141–1143. doi: 10.1016/0277-5379(89)90406-9. [DOI] [PubMed] [Google Scholar]
  8. McNeil B. J., Hanley J. A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making. 1984;4(2):137–150. doi: 10.1177/0272989X8400400203. [DOI] [PubMed] [Google Scholar]
  9. Mims M. P., Morrisett J. D., Mattioli C. A., Gotto A. M., Jr Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma. N Engl J Med. 1989 Jun 1;320(22):1452–1457. doi: 10.1056/NEJM198906013202204. [DOI] [PubMed] [Google Scholar]
  10. Nicholson J. K., Nicholson F. Proton spectroscopy of plasma and testing for malignancy. Lancet. 1987 Aug 1;2(8553):280–281. doi: 10.1016/s0140-6736(87)90871-3. [DOI] [PubMed] [Google Scholar]
  11. Okunieff P., Zietman A., Kahn J., Singer S., Neuringer L. J., Levine R. A., Evans F. E. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med. 1990 Apr 5;322(14):953–958. doi: 10.1056/NEJM199004053221403. [DOI] [PubMed] [Google Scholar]
  12. Otvos J. D., Jeyarajah E. J., Hayes L. W., Freedman D. S., Janjan N. A., Anderson T. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer. Clin Chem. 1991 Mar;37(3):369–376. [PubMed] [Google Scholar]
  13. Peeling J., Sutherland G., Marat K., Tomchuk E., Bock E. 1H and 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms. J Neurosurg. 1988 Jun;68(6):931–937. doi: 10.3171/jns.1988.68.6.0931. [DOI] [PubMed] [Google Scholar]
  14. Swets J. A. Measuring the accuracy of diagnostic systems. Science. 1988 Jun 3;240(4857):1285–1293. doi: 10.1126/science.3287615. [DOI] [PubMed] [Google Scholar]
  15. Wilding P., Senior M. B., Inubushi T., Ludwick M. L. Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy. Clin Chem. 1988 Mar;34(3):505–511. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES